Mumbai, April 21,2018: Pharma Major, Cipla Ltd ssaid that US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Company’s Indore formulations facility from April 2, 2018 till April 13, 2018.
This was in the normal course of business. There were no data integrity and or repeat observations.
The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.
United News of India
